PDS Biotechnology Corporation
PDSB
Get informed when a big investor buys or sells
+ FollowMarket Cap$61.96M
Close$
$0.21
81% downside
Current Fair Value
81% downsideOvervalued by 81% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $61.96 Million |
|---|---|
| Enterprise Value | $-1,170,626,625.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.74 |
| Beta | 1.45 |
| Outstanding Shares | 55,659,669 |
Return
| Return on Equity | 1.01% |
|---|---|
| Return on Assets | -0.41% |
| Return on Invested Capital | 228.54% |
Valuation & Multiples
| P/E Ratio | -1.73 |
|---|---|
| PEG | -51.72 |
| Price to Sales | - |
| Price to Book Ratio | -0.02 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.14 |
| Enterprise Value to Net Income | 32 |
| Total Debt to Enterprise | -3.73 |
| Debt to Equity | -1.22 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.11
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 343,600▲ 4.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 13.82%▲ 4.72% |
|---|---|
| Total Invested | $6.78M▲ 121.91% |
| Investors Holding | 53▲ 11.00% |
ESG Score
No data
About PDS Biotechnology Corporation
CEO: Frank Bedu-Addo Under normal circumstances, the fund will invest at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities and derivative instruments that provide exposure to equity securities. To gain this exposu...